Nervous System News and Research

Latest Nervous System News and Research

Brain stem cells shown to generate multiple new brain stem cells

A Johns Hopkins team has discovered in young adult mice that a lone brain stem cell is capable not only of replacing itself and giving rise to specialized neurons and glia – important types of brain cells – but also of taking a wholly unexpected path: generating two new brain stem cells.

30 Jun 2011

Almirall, Forest Labs submit aclidinium bromide NDA to FDA for treatment of COPD

Forest Laboratories, Inc. and Almirall, S.A. announced they have recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for aclidinium bromide, a long-acting inhaled antimuscarinic agent developed for the treatment of COPD.

30 Jun 2011

Sensitivity of bladder cancer cells linked to chemotherapy and expression of miR-34a gene

Researchers at the UC Davis Cancer Center have discovered a way of sensitizing muscle-invasive bladder cancer cells so that they succumb to the toxic effects of chemotherapy. The finding adds to mounting evidence that tiny strands of RNA - called microRNA - play key roles in some of the deadliest types of cancer.

30 Jun 2011

Mary Ann Liebert peer-reviewed journal highlights advances in gene therapy for neurological diseases

Novel tools and methods for delivering therapeutic genes to cells in the central nervous system hold great promise for the development of new treatments to combat incurable neurologic diseases.

30 Jun 2011

FDA's ODAC recommends withdrawal of Avastin approval for metastatic breast cancer

Genentech, a member of the Roche Group, announced today that, during a U.S. Food and Drug Administration (FDA) hearing, the FDA's Oncologic Drugs Advisory Committee (ODAC) recommended that the FDA withdraw its approval of Avastin in combination with paclitaxel chemotherapy for previously untreated HER2-negative metastatic breast cancer.

30 Jun 2011

Emotional empathy linked to physiological responses to angry faces

Egocentric, self-centred, and insensitive to the needs of others: these social problems often arise in people with severe traumatic brain injury (TBI) and have been attributed in part to a loss of emotional empathy, the capacity to recognise and understand the emotions of other people.

29 Jun 2011

Anacor, DNDi and SCYNEXIS complete SCYX-7158 pre-clinical studies for combating sleeping sickness

Anacor Pharmaceuticals, the Drugs for Neglected Diseases initiative (DNDi), and SCYNEXIS Inc. today announced the successful completion of pre-clinical studies for the first new oral drug candidate discovered specifically to combat human African trypanosomiasis (HAT), also known as sleeping sickness.

29 Jun 2011

New concepts for how evolutionary change occurs

At a recent Kavli Futures Symposium, 19 experts from a diverse range of fields discussed the promise of using the lab to understand and exploit the evolution of organisms -- progress that may one day lead to new vaccines or other biotechnology products.

29 Jun 2011

Genetic tools that enable cell type-specific delivery hold promise for combating incurable neurologic diseases

Novel tools and methods for delivering therapeutic genes to cells in the central nervous system hold great promise for the development of new treatments to combat incurable neurologic diseases. Five of the most exciting developments in this rapidly advancing field are presented in a series of articles in the June issue of Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc..

29 Jun 2011

BioLineRx initiates enrollment in BL-1020 Phase II/III trial against schizophrenia

BioLineRx, a biopharmaceutical development company, announced today the enrollment of the first patient in the Phase II/III CLARITY clinical trial of BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia.

28 Jun 2011

TrialNet presents Diamyd Phase II study results on type 1 diabetes at ADA 2011

The American research consortium Type 1 Diabetes TrialNet presented their results of a Phase II study with the antigen-based diabetes therapy Diamyd yesterday, June 27, at the American Diabetes Association 71st Scientific Sessions (ADA) in San Diego, California, USA, after the closing of the stock market.

28 Jun 2011

Omeros identifies compounds that interact with orphan GPCRs associated with leukemia

Omeros Corporation today reported that it has identified compounds that interact with orphan G protein-coupled receptors (GPCRs) P2Y8 and OPN4. P2Y8 (also known as P2RY8) is associated with acute lymphoblastic leukemia (ALL), an aggressive cancer of the white blood cells.

27 Jun 2011

New 3D herpes infection model brings hope

Herpes infections on the lips, in the eyes or on the nose are painful, long-lasting and unpleasant. A new 3D herpes infection model brings hope: active ingredients and new treatments can be reliably tested with this model. Animal tests could soon be a thing of the past.

27 Jun 2011

EnVivo initiates EVP-0962 GSM Phase 1 clinical trial for Alzheimer’s disease

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, announced today that it recently initiated a Phase 1 clinical trial of EVP-0962, its potent and selective gamma secretase modulator (GSM), in healthy volunteers.

27 Jun 2011

Acorda to move corporate headquarters to Ardsley Park life science campus

Acorda Therapeutics, Inc. today announced that it plans to relocate its corporate headquarters to the Ardsley Park life science campus in Ardsley, New York, which was acquired by BioMed Realty Trust, Inc..

27 Jun 2011

Yissum, BioLineRx sign license deal to develop and commercialize BL-7040 for IBD

BioLineRx, a biopharmaceutical drug development company, and Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that they have signed a worldwide, exclusive license agreement for BioLineRx to develop and commercialize BL-7040, an orally available Phase II ready molecule for treating Inflammatory Bowel Disease (IBD) and other inflammatory diseases.

27 Jun 2011

Anticholinergic medications linked to risk of cognitive impairment, death in older population

A large, long-term study confirms that medications with anticholinergic activity, which include many drugs frequently taken by older adults, cause cognitive impairment. The research is also the first to identify a possible link between these drugs - which include over-the-counter and prescription sleep aids and incontinence treatments - and risk of death.

27 Jun 2011

Maternal MS not linked with poor pregnancy or birth outcomes

Canadian researchers have found that maternal multiple sclerosis (MS) is generally not associated with adverse delivery outcomes or risk to their offspring. Full findings now appear in Annals of Neurology, a journal published by Wiley-Blackwell on behalf of the American Neurological Association.

27 Jun 2011

McMaster researchers to use tiny worms for Parkinson's project

McMaster researchers from three disciplines are deploying thousands of tiny worms and a homegrown invention to test drugs in a collaborative bid to defeat Parkinson's Disease.

27 Jun 2011

Department of Defense awards Impel Phase II SBIR grant for blood-brain barrier bypass technology

Impel NeuroPharma, a medical device company whose technology is designed to enable pharmaceutical drugs to bypass the blood-brain barrier and enter the central nervous system (CNS), today announced that it was selected to receive a Phase II Small Business Investigational Research (SBIR) grant from the Department of Defense's Chemical and Biological Defense SBIR Program entitled, "Blood Brain Barrier Drug Delivery of Therapeutics for Chemical Warfare Agents."

24 Jun 2011

Nervous System News and Research

Latest Nervous System News and Research

Brain stem cells shown to generate multiple new brain stem cells

Almirall, Forest Labs submit aclidinium bromide NDA to FDA for treatment of COPD

Sensitivity of bladder cancer cells linked to chemotherapy and expression of miR-34a gene

Mary Ann Liebert peer-reviewed journal highlights advances in gene therapy for neurological diseases

FDA's ODAC recommends withdrawal of Avastin approval for metastatic breast cancer

Emotional empathy linked to physiological responses to angry faces

Anacor, DNDi and SCYNEXIS complete SCYX-7158 pre-clinical studies for combating sleeping sickness

New concepts for how evolutionary change occurs

Genetic tools that enable cell type-specific delivery hold promise for combating incurable neurologic diseases

BioLineRx initiates enrollment in BL-1020 Phase II/III trial against schizophrenia

TrialNet presents Diamyd Phase II study results on type 1 diabetes at ADA 2011

Omeros identifies compounds that interact with orphan GPCRs associated with leukemia

New 3D herpes infection model brings hope

EnVivo initiates EVP-0962 GSM Phase 1 clinical trial for Alzheimer’s disease

Acorda to move corporate headquarters to Ardsley Park life science campus

Yissum, BioLineRx sign license deal to develop and commercialize BL-7040 for IBD

Anticholinergic medications linked to risk of cognitive impairment, death in older population

Maternal MS not linked with poor pregnancy or birth outcomes

McMaster researchers to use tiny worms for Parkinson's project

Department of Defense awards Impel Phase II SBIR grant for blood-brain barrier bypass technology

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Nervous System News and Research

Latest Nervous System News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in